OCY Stock Overview
A precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Oncimmune Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.17 |
| 52 Week High | UK£0.33 |
| 52 Week Low | UK£0.10 |
| Beta | 1.26 |
| 11 Month Change | 1.19% |
| 3 Month Change | -15.84% |
| 1 Year Change | -35.11% |
| 33 Year Change | -90.86% |
| 5 Year Change | -68.81% |
| Change since IPO | -88.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | -35.1% | -18.3% | 8.6% |
Return vs Industry: OCY underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: OCY underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| OCY volatility | |
|---|---|
| OCY Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OCY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OCY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 38 | Martin Gouldstone | www.oncimmune.com |
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. It offers ImmunoINSIGHTS, an autoantibody profiling service that unlocks the immune system to discover and convert autoantibodies into actionable biomarkers; Sero Tag, a discovery engine which identifies relevant biomarker pool for target discovery or companion diagnostics; NavigAID, a creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. The company also provides business development and marketing services.
Oncimmune Holdings plc Fundamentals Summary
| OCY fundamental statistics | |
|---|---|
| Market cap | €20.57m |
| Earnings (TTM) | -€3.76m |
| Revenue (TTM) | €1.46m |
14.1x
P/S Ratio-5.5x
P/E RatioIs OCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCY income statement (TTM) | |
|---|---|
| Revenue | UK£1.21m |
| Cost of Revenue | UK£445.00k |
| Gross Profit | UK£769.00k |
| Other Expenses | UK£3.91m |
| Earnings | -UK£3.14m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 63.34% |
| Net Profit Margin | -258.65% |
| Debt/Equity Ratio | -404.9% |
How did OCY perform over the long term?
See historical performance and comparison